
Organogenesis Holdings (ORGO) Stock Forecast & Price Target
Organogenesis Holdings (ORGO) Analyst Ratings
Bulls say
Organogenesis Holdings is a regenerative medicine company with a focus on advanced wound care and sports medicine markets, whose product portfolio includes a range of established solutions such as Apligraf and Dermagraft. Despite facing mixed performance due to market dynamics and impending changes in reimbursement structures, the company is expected to achieve improved operating profits and valuation as it continues to produce solid results. Projections suggest that as reimbursement rates stabilize and the market consolidates, Organogenesis Holdings is well-positioned to capture additional market share, contributing to a positive outlook for its stock.
Bears say
Organogenesis Holdings Inc. faces significant headwinds that contribute to a negative outlook, primarily due to the anticipated lack of improvement in operational efficiency, particularly concerning research and development costs in FY26. Additionally, the company is vulnerable to various external risks, including potential underperformance in PuraPly sales, unfavorable Medicare Part B pricing for amniotic products, and increased competition that may hinder market share growth. Lastly, challenges from Medicare Administrative Contractors, slow adoption of new products, and adverse clinical data outcomes further exacerbate the concerns regarding the company's future financial performance.
This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.
Organogenesis Holdings (ORGO) Analyst Forecast & Price Prediction
Start investing in Organogenesis Holdings (ORGO)
Order type
Buy in
Order amount
Est. shares
0 shares